Adverse Outcome Pathways Mechanistically Describing Hepatotoxicity
- PMID: 39312169
- DOI: 10.1007/978-1-0716-4003-6_12
Adverse Outcome Pathways Mechanistically Describing Hepatotoxicity
Abstract
Adverse outcome pathways (AOPs) describe toxicological processes from a dynamic perspective by linking a molecular initiating event to a specific adverse outcome via a series of key events and key event relationships. In the field of computational toxicology, AOPs can potentially facilitate the design and development of in silico prediction models for hazard identification. Various AOPs have been introduced for several types of hepatotoxicity, such as steatosis, cholestasis, fibrosis, and liver cancer. This chapter provides an overview of AOPs on hepatotoxicity, including their development, assessment, and applications in toxicology.
Keywords: AOP; Cancer; Cholestasis; Fibrosis; Liver toxicity; Steatosis.
© 2025. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
Adverse Outcome Pathways as Versatile Tools in Liver Toxicity Testing.Methods Mol Biol. 2022;2425:521-535. doi: 10.1007/978-1-0716-1960-5_20. Methods Mol Biol. 2022. PMID: 35188645
-
Adverse Outcome Pathways as Tools to Assess Drug-Induced Toxicity.Methods Mol Biol. 2016;1425:325-37. doi: 10.1007/978-1-4939-3609-0_14. Methods Mol Biol. 2016. PMID: 27311472 Free PMC article.
-
Development of an adverse outcome pathway from drug-mediated bile salt export pump inhibition to cholestatic liver injury.Toxicol Sci. 2013 Nov;136(1):97-106. doi: 10.1093/toxsci/kft177. Epub 2013 Aug 14. Toxicol Sci. 2013. PMID: 23945500
-
Drug-Induced Fatty Liver Disease (DIFLD): A Comprehensive Analysis of Clinical, Biochemical, and Histopathological Data for Mechanisms Identification and Consistency with Current Adverse Outcome Pathways.Int J Mol Sci. 2024 May 10;25(10):5203. doi: 10.3390/ijms25105203. Int J Mol Sci. 2024. PMID: 38791241 Free PMC article. Review.
-
The identification of nuclear receptors associated with hepatic steatosis to develop and extend adverse outcome pathways.Crit Rev Toxicol. 2016 Feb;46(2):138-52. doi: 10.3109/10408444.2015.1089471. Epub 2015 Oct 9. Crit Rev Toxicol. 2016. PMID: 26451809 Review.
Cited by
-
Adverse Outcome Pathway and Machine Learning to Predict Drug Induced Seizure Liability.ACS Chem Neurosci. 2025 Jun 4;16(11):2085-2099. doi: 10.1021/acschemneuro.5c00177. Epub 2025 May 14. ACS Chem Neurosci. 2025. PMID: 40366155
References
-
- U.S. (2018) Strategic plan to promote the development and implementation of alternative test methods within the TSCA program, Environmental Protection Agency, United States
MeSH terms
LinkOut - more resources
Full Text Sources
Medical